| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|
|
01550615
Member |
05-Dec-2007 09:22
|
|
x 0
x 0 Alert Admin |
Deutche Bank issue call warrant exercise price 85 cts. This is a European Bk. I think they probably know that CE is coming!!!
|
| Useful To Me Not Useful To Me | |
|
cashiertan
Elite |
05-Dec-2007 09:20
|
|
x 0
x 0 Alert Admin |
This stock prove to me i should bought it. entered at 0.73 and 0.745. exited half at 0.79 |
| Useful To Me Not Useful To Me | |
|
|
|
|
A02041315
Senior |
05-Dec-2007 09:17
|
|
x 0
x 0 Alert Admin |
CHEONG!!!!!!!!!!!!!SHA!SHA!SHA!!!!!  
CE ON THE WAY!!!!!!!!!!!  
|
| Useful To Me Not Useful To Me | |
|
novena_33
Veteran |
05-Dec-2007 09:13
|
|
x 0
x 0 Alert Admin |
 must feed more ok.....
|
| Useful To Me Not Useful To Me | |
|
poppy_toyz
Member |
05-Dec-2007 09:07
|
|
x 0
x 0 Alert Admin |
This Crazy Horse shot up to 0.80 early in the morning. And then slowed down and buckle.... Did it took Viargra last nite? |
| Useful To Me Not Useful To Me | |
|
|
|
|
allright
Senior |
04-Dec-2007 15:19
|
|
x 0
x 0 Alert Admin |
Thank You |
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
04-Dec-2007 11:24
|
|
x 0
x 0 Alert Admin |
The last time BIG transfer technology for Guidant's Champion DES. Later on, Guidant use the everolimus drug on their best BMS platform "Multi-Link". I don't think Abbott will be paying BIG royalties. Xience has been selling in CE approved countries already and if there is royalty payment, BIG would have booked them already. Most of these DES majors have not much self- invention capability and need to transfer technology from other smaller players/ IP holders. Only BIG has true proprietary IP, technology and patents. |
| Useful To Me Not Useful To Me | |
|
allright
Senior |
04-Dec-2007 10:45
|
|
x 0
x 0 Alert Admin |
You are truly well informed. Sigh really must be patient with this stock. As to my earlier question(sorry I am new in this market but like what you have been writing about BIG and made MY OWN DECISION to buy based on your reaearch)...does xience have to pay royalty to BIG as mentioned by you in your earlier postings? or did they sell it outright to Guidant? |
| Useful To Me Not Useful To Me | |
|
|
|
|
bengster68
Master |
04-Dec-2007 02:41
|
|
x 0
x 0 Alert Admin |
GAITHERSBURG, Md., Nov 29 (Reuters) - Abbott Laboratories Inc (ABT.N: Quote, Profile, Research) moved closer to joining the U.S. market for drug-coated heart stents on Thursday as an advisory panel backed the company's experimental device. A committee of advisers to the Food and Drug Administration voted 9-1 to recommend approval of Abbott's product, called Xience, despite uncertainty about the long-term risks of blood clots. That issue has weighed heavily on the once $6-billion-a-year market for drug-coated stents. Most of the outside experts said the Xience device appeared reasonably safe for the first year after it was implanted. "The early safety data are reassuring. Beyond that we simply need more information," said Dr. Clyde Yancy, the panel's chairman and a Baylor University cardiologist. The FDA usually follows panel recommendations, and Abbott has said it expects to launch Xience in the United States in the first half of 2008. Now, Johnson & Johnson's (JNJ.N: Quote, Profile, Research) Cypher and Boston Scientific's (BSX.N: Quote, Profile, Research) Taxus are the only two U.S.-approved drug-coated stents. Abbott and Medtronic Inc (MDT.N: Quote, Profile, Research), with its Endeavor stent, are seeking to join the field. Stents are tiny mesh tubes that doctors insert to prop open arteries after clearing them of blockages. Drug coating was added to newer versions starting in 2003 to keep the vessels from reclogging. The use of drug-coated stents has been hurt by a rare but serious risk of blood clots developing months, or more than a year, after doctors implant the devices. Blood clots may lead to heart attacks. The blood-clot risk with Xience is unclear, several panel members said, noting the company provided limited data on 422 patients who had the Xience device implanted for two years. "I thought the safety data in 12 to 24 months was inadequate and it was a bad precedent to establish," said Dr. John Somberg, the lone panel member to vote against Xience. Based on the available data through two years, the rate of blood clots for Xience and Taxus was similar, about 1.3 percent using one of the standard clotting definitions. The committee urged a large post-approval study to better gauge the chances of developing a blood clot with Xience. Committee members agreed that Abbott's studies to date showed Xience was effective at keeping arteries clear and some saw advantages over Taxus, the current market leader. "I think (Xience) represents a step forward," said Dr. Richard Page, a panel member and cardiologist at the University of Washington School of Medicine in Seattle. Many Wall Street analysts predict Xience will eventually become the top-selling drug-coated stent. "For 2008 in the U.S., I'm looking for about $520 million in total Xience sales," RBC Capital Markets analyst Phil Nalbone said. That would represent about 22 percent of the drug-coated stent market in the United States and assumes a Xience launch late in the first quarter of 2008, he said. Stanford Group managing director Jan Wald said Xience could lead the U.S. market in six months to a year and expects the stent to capture market share in excess of 25 percent. Abbott acquired Xience from Guidant Corp when Boston Scientific bought Guidant in 2006 and divested the Guidant vascular business. As part of the deal, Boston Scientific would market Xience alongside Taxus, but would call the new product Promus and return 40 percent of gross profits from Promus to Abbott. The panel vote was "very encouraging," Abbott Executive Vice President John Capek said in a statement. Boston Scientific also welcomed the decision. Xience already is sold in other countries. In October, an FDA advisory panel unanimously urged approval for Medtronic's Endeavor stent. Medtronic has said it expects final FDA clearance by year end. Abbott shares rose 70 cents, or 1.2 percent, in extended trading from their $57 official close on the New York Stock Exchange. (Reporting by Lisa Richwine and Lisa Baertlein; Editing by Marguerite Choy, Gary Hill) *** Even a lousy DES can make tons of money after approval. And the best DES still kena stuck at pathetic CE approval after so many years. Imagine what will happen if Biomatrix gets its regulatory approval or bought up by bigger rival that can have powerful lobbying to speed up the approval process. |
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
04-Dec-2007 02:14
|
|
x 0
x 0 Alert Admin |
I just came back from overseas. Some analysts predict Xience will capture 50% market share of DES. Let me just say again that Xience V is still a second rated DES compared to Biomatrix. Xience V has the deadly late-thrombosis problem that is plaguing current top 2 DES. Plus, Xience V is using everolimus, the drug the BIG discarded years ago and BIG is using their proprietary patented Biolimus A9. Obviously Biolimus A9 is a better drug than Everolimus. Xience V can go and stand one corner if there is a RCT with Biomatrix. Shrot term efficacy of Biomatrix is more superior than Xience and Biomatrix has zero late-thrombosis problem (reverts back to BMS after 6 months). Those guys in US haven't see the real DES king. 9/10 vote by FDA panel is very high (i feel they are disregarding certain serious safety concerns) ...... it just shows how desperate the US market is waiting for another alternative DES. Let Xience and Endeavor be approved. It will only make JNJ more hard up for BIG. Remember only BIG's proven stent technology can save JNJ and bring JNJ back to the number one spot again. Without BIG, JNJ will be totally out of the DES industry soon |
| Useful To Me Not Useful To Me | |
|
cashiertan
Elite |
03-Dec-2007 10:20
|
|
x 0
x 0 Alert Admin |
no leg to pull liao, now this counter dun like me to buy him. he thinks he is not good enough for my $. how mani? want to buy also cannot. he want me to earn $ from daily interest from money market. |
| Useful To Me Not Useful To Me | |
|
Impossible
Member |
03-Dec-2007 10:15
|
|
x 0
x 0 Alert Admin |
Count down to Jan 08......19 more trading days to go... 1 
|
| Useful To Me Not Useful To Me | |
|
|
|
|
Manikamaniko.
Master |
03-Dec-2007 00:02
|
|
x 0
x 0 Alert Admin |
Cashier... I was only pulling your legs... :) |
| Useful To Me Not Useful To Me | |
|
cashiertan
Elite |
02-Dec-2007 16:45
|
|
x 0
x 0 Alert Admin |
i prefer buy high sell higher. in the market like now, a bottom can be virtually erased with one bad volatile days. i rather wait for confirmed signal before entry. furthermore there is heavy resistant at 0.72 area. |
| Useful To Me Not Useful To Me | |
|
Manikamaniko.
Master |
02-Dec-2007 09:41
|
|
x 0
x 0 Alert Admin |
Cashier... :) hahaha... cheap-cheap you don't buy, but must buy when it is expensive... hehehe... |
| Useful To Me Not Useful To Me | |
|
huatah
Veteran |
01-Dec-2007 21:23
|
|
x 0
x 0 Alert Admin |
Hmm... guess is time for me to buy in to lower down my average... wat a waste.. back tracking.. saw tis counter hit below 0.7... during my holiday trip.. would have secured it during then.. haiz.. |
| Useful To Me Not Useful To Me | |
|
cashiertan
Elite |
30-Nov-2007 20:45
|
|
x 0
x 0 Alert Admin |
relac leh, wait for it to break 0.725 1st and can hold abv 0.72 then consider enter. |
| Useful To Me Not Useful To Me | |
|
A02041315
Senior |
30-Nov-2007 16:20
|
|
x 0
x 0 Alert Admin |
RING!RING!RING! Last call for BIG UP UPUP
Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! |
| Useful To Me Not Useful To Me | |
|
allright
Senior |
30-Nov-2007 10:24
|
|
x 0
x 0 Alert Admin |
If bios will collect royalty from Abbott why isnt there an announcement from Biosensors then? |
| Useful To Me Not Useful To Me | |
|
01550615
Member |
30-Nov-2007 10:01
|
|
x 0
x 0 Alert Admin |
Time to buy and keep!!! waiting for CE now!!!
|
| Useful To Me Not Useful To Me | |
